EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Interim Estimates of 2024–2025 Seasonal Influenza Vaccine Effectiveness in Germany—Data From Primary Care and Hospital Sentinel Surveillance

Annika Erdwiens, Carolin Hackmann iD, Marianne Wedde, Barbara Biere, Janine Reiche iD, Ute Preuß, Kristin Tolksdorf, Silke Buda, Ralf Dürrwald iD

Influenza and Other Respiratory Viruses · 2025

DOI: 10.1111/irv.70115 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2025. Verfasst von Annika Erdwiens und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department 3 Infectious Disease Epidemiology, Unit 36 Respiratory Infections, Robert Koch Institute, Berlin, Germany. Hauptthemen laut MEDLINE: Influenza, Human, Influenza Vaccines, Primary Health Care, Vaccine Efficacy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Federal Ministry of Health, European Centre for Disease Prevention and Control (ECDC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Between October 2024 and February 2025, influenza A(H1N1)pdm09 initially predominated in Germany, with subsequent co‐circulation of influenza B/Victoria. We provide interim estimates of 2024/2025 influenza vaccine effectiveness (VE) in Germany across primary care and secondary care. VE against any influenza in primary care was 31% (95% CI: 1–52). Interim VE was high against influenza B; however, interim estimations indicated a much lower VE against influenza A especially in the adult age group below 60 years. In secondary care, VE against any influenza was 69% (95% CI: 21–88). Our findings support promoting influenza vaccination alongside infection‐preventing behavior and prompt antiviral therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza, HumanInfluenza VaccinesPrimary Health CareVaccine EfficacyHumansGermanySentinel SurveillanceMiddle AgedAdultAdolescentYoung AdultChild, PreschoolAgedChildMaleFemaleSeasonsInfantInfluenza A Virus, H1N1 SubtypeInfluenza B virusAged, 80 and overVaccinationHospitals

Stichwörter der Autor:innen

hospitalizationinfluenzaprimary carevaccinevaccine effectiveness

Substanzen

Influenza Vaccines

Autor:innen und Institutionen

  • Department 3 Infectious Disease Epidemiology, Unit 36 Respiratory Infections, Robert Koch Institute, Berlin, Germany.
  • Department 1 Infectious Diseases, Unit 17 Influenza Viruses and Other Respiratory Viruses, Robert Koch Institute, Berlin, Germany.

ORCID-Profile: Carolin Hackmann, Janine Reiche, Ralf Dürrwald

Förderung

  • German Federal Ministry of Health
  • European Centre for Disease Prevention and Control (ECDC)

Zitieren

APA

Erdwiens, A., Hackmann, C., Wedde, M., Biere, B., Reiche, J., Preuß, U., Tolksdorf, K., Buda, S., & Dürrwald, R. (2025). Interim Estimates of 2024–2025 Seasonal Influenza Vaccine Effectiveness in Germany—Data From Primary Care and Hospital Sentinel Surveillance. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70115

Vancouver

Erdwiens A, Hackmann C, Wedde M, Biere B, Reiche J, Preuß U, et al. Interim Estimates of 2024–2025 Seasonal Influenza Vaccine Effectiveness in Germany—Data From Primary Care and Hospital Sentinel Surveillance. Influenza and Other Respiratory Viruses. 2025. doi:10.1111/irv.70115

BibTeX
@article{Erdwiens2025,
  author = {Erdwiens, Annika and Hackmann, Carolin and Wedde, Marianne and Biere, Barbara and Reiche, Janine and Preuß, Ute and Tolksdorf, Kristin and Buda, Silke and Dürrwald, Ralf},
  title = {Interim Estimates of 2024–2025 Seasonal Influenza Vaccine Effectiveness in Germany—Data From Primary Care and Hospital Sentinel Surveillance},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2025},
  doi = {10.1111/irv.70115}
}
Kostenlos starten →